Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

BioAge Labs (BIOA) EBIAT (2023 - 2026)

BioAge Labs' EBIAT history spans 2 years, with the latest figure at -$25.9 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 22.78% to -$25.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$80.6 million, a 13.35% decrease, with the full-year FY2025 number at -$80.6 million, down 13.35% from a year prior.
  • EBIAT hit -$25.9 million in Q4 2025 for BioAge Labs, down from -$20.2 million in the prior quarter.
  • Over the last five years, EBIAT for BIOA hit a ceiling of -$12.9 million in Q1 2025 and a floor of -$25.9 million in Q4 2025.